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ORIGINAL ARTICLE
Hemopoietic-speciﬁc Sf3b1-K700E knock-in mice display the
splicing defect seen in human MDS but develop anemia
without ring sideroblasts
A Mupo1,14, M Seiler2,14, V Sathiaseelan3, A Pance4, Y Yang1, AA Agrawal2, F Iorio5, R Bautista6, S Pacharne1, K Tzelepis1, N Manes1,
P Wright7, E Papaemmanuil8, DG Kent3, PC Campbell9, S Buonamici2, N Bolli9,10,11,14 and GS Vassiliou1,12,13,14
Heterozygous somatic mutations affecting the spliceosome gene SF3B1 drive age-related clonal hematopoiesis, myelodysplastic
syndromes (MDS) and other neoplasms. To study their role in such disorders, we generated knock-in mice with hematopoietic-
speciﬁc expression of Sf3b1-K700E, the commonest type of SF3B1mutation in MDS. Sf3b1K700E/+ animals had impaired erythropoiesis
and progressive anemia without ringed sideroblasts, as well as reduced hematopoietic stem cell numbers and host-repopulating
ﬁtness. To understand the molecular basis of these observations, we analyzed global RNA splicing in Sf3b1K700E/+ hematopoietic
cells. Aberrant splicing was associated with the usage of cryptic 3′ splice and branchpoint sites, as described for human SF3B1
mutants. However, we found a little overlap between aberrantly spliced mRNAs in mouse versus human, suggesting that anemia
may be a consequence of globally disrupted splicing. Furthermore, the murine orthologues of genes associated with ring
sideroblasts in human MDS, including Abcb7 and Tmem14c, were not aberrantly spliced in Sf3b1K700E/+ mice. Our ﬁndings
demonstrate that, despite signiﬁcant differences in affected transcripts, there is overlap in the phenotypes associated with SF3B1-
K700E between human and mouse. Future studies should focus on understanding the basis of these similarities and differences as a
means of deciphering the consequences of spliceosome gene mutations in MDS.
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INTRODUCTION
The myelodysplastic syndromes (MDS) are clonal blood disorders
characterized by dysplastic hematopoiesis and blood cytopenias.1
Somatic mutations affecting the genes SF3B1, SRSF2, U2AF1, ZRSR2
and LUC7L2, which code for components of the spliceosome, are
found in more than half of MDS patients.2,3 SF3B1 mutations are
the commonest among these and are associated with the
presence of bone marrow ringed sideroblasts2 and a favorable
prognosis.4,5 The mutations are missense, heterozygous and
cluster strongly within HEAT domains 4–8 of the protein,
suggesting that they may be neomorphic gain-of-function
variants.2 Studies analyzing the subclonal composition of MDS
indicate that SF3B1 mutations represent early/initiating lesions in
MDS evolution,5–7 and this was corroborated by their recent
identiﬁcation in hematopoietic cell clones found in at least 2% of
otherwise healthy individuals aged 70 years or older.8 Further-
more, in a signiﬁcant proportion of SF3B1-mutant MDS this is the
only identiﬁable driver mutation,7,9 suggesting that in the right
context these mutations can impart a substantial ﬁtness
advantage on hematopoietic stem cells. However, the molecular
effects of SF3B1 mutations and the mechanisms through which
they drive clonal expansion and dyserythropoiesis remain obscure.
RNA splicing takes place at splice sites (ss) located at the 5′ and 3′
ends of introns, after the recognition of consensus nucleotide
sequences by the spliceosome machinery. The U1 small nuclear
ribonucleoprotein particle (snRNP) recognizes the 5′ ss, and at the
3′ ss the polypyrimidine (Py) tract and an invariant AG dinucleotide
located at the intron-exon junction are recognized by the U2AF1–
U2AF2 complex, while the proximal branch point sequence (BPS) is
identiﬁed by the U2 snRNP, of which SF3B1 is a component.10 MDS
cases associated with SF3B1 mutations show a distinct gene
expression proﬁle, including dysregulation of genes required for
heme biosynthesis, such as ALAS2 and ABCB7.11,12 Furthermore, it
was recently demonstrated in primary human cancers and cell lines
that SF3B1 mutations are associated with aberrant splicing through
recognition of alternative 3′ ss located around 10–25 nt upstream of
the canonical 3′ ss.13 However, the consequences of these
aberrations and their impact on hematopoiesis are not well
understood.
Here, to investigate the molecular and phenotypic conse-
quences of SF3B1 mutations on hematopoiesis, we generate and
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study an accurate conditional knock-in mouse model of SF3B1-
K700E, the commonest mutation in MDS. Our ﬁndings show that
while the sequence features of the aberrant splicing are extremely
similar between mouse and human,13 the genes affected differ
signiﬁcantly. Despite these marked differences, Sf3b1K700E/+ mice
did go on to develop progressive anemia, a central feature of
SF3B1-mutant MDS. However, other characteristic features of
SF3B1-mutant MDS such as ring sideroblasts and a stem cell
growth advantage were not observed. Our results propose that
the anemia associated with mutant SF3B1 may be a consequence
of globally disrupted splicing rather than effects on particular
genes while other features of SF3B1-mutant MDS may be gene-
speciﬁc.
MATERIALS AND METHODS
Generation of the Sf3b1-K700E targeting construct
The targeting construct was generated using gateway and recombineering
recombination technologies as described previously.14 Brieﬂy, a pool of
two BACs containing the region of interest of the Sf3b1 locus, RP24-64H9
and RP24-439B17, were used to generate the gateway-adapted inter-
mediate plasmid by inserting the ‘U’ and ‘G’ cassettes.14 The latter were
generated by PCR and the ‘U’ cassette inserted into the BAC ﬁrst so that
the ‘G’ cassette then retrieved the relevant portion of the Sf3b1 locus into a
gateway-adapted intermediate plasmid.15 The endogenous exon 15 was
then replaced with a synthetic one bearing the A4G mutation encoding
for the K700E variant. The synthetic DNA was made by GeneArt (Life
Technologies, Regensburg, Germany), and was subcloned into the
intermediate vector exploiting two KpnI sites in introns 14 and 16
(Supplementary Figure 1). The splice trap cassette encoding an Engrail-2
splice acceptor site, codon-optimized exons 12–15, intron 15, codon-
optimized exons 15–19, intron 19 and native exons 20–25 (including the
3′ UTR) was synthesized by GeneArt (Life Technologies) and subcloned
into the pL1L2_BactP vector previously modiﬁed to remove the EnSA-IRES-
lacZ-pA-LoxP and subsequently the 3′ LoxP site by digestion. The ﬁnal
targeting vector was built using the two vectors above and the pL3L4-DTA
vector14 in a multi-vector gateway reaction, and was linearized prior to
electroporation using the AsisI restriction site (Supplementary Figure 2).
Sequences of primers used to generate and validate the targeting
construct are given in Supplementary Table 1.
ES cell culture and validation of clones
JM8 ES cells were used for electroporation of the ﬁnal targeting vector.
Cells were grown for 9 days after electroporation in a feeder-coated plate
with DMEM medium (Invitrogen, Hempstead, UK) supplemented with 10%
FBS (Biosera, UK), 1% BME (Sigma-Aldrich, Haverhill, UK), 1000 U/ml
leukemia inhibitory factor (ESGRO, Millipore, UK) and G418 (Sigma-Aldrich)
180 μg/ml. Clones were picked and replated in a 96-well plate with feeders,
split in replica plates after 5 days, and lysis for DNA extraction was
performed after seven additional days. Clones were screened by 5′ and 3′
long-range PCR (Supplementary Figure 3). Three clones with successful 5′
and 3′ ampliﬁcation, were and all showed that the splice-trap cassette was
indeed functional (Supplementary Figure 4a and b). ES cell clones post
exposure to FLP and Cre recombinases were validated for excision of the
positive selection marker and cDNA splice-trap cassette, respectively
(Supplementary Figure 4c). To conﬁrm that the K700E mutation was not
expressed in basal conditions but only after Cre expression, cDNA from clone
D9 pre- and post- excision of the splice trap cassette was sequenced
(Supplementary Figure 4d).
Hematological measurements and mouse survival
Blood counts were performed using a VetABC analyzer (Horiba ABX,
Montpellier, France). Mice were monitored daily and culled if they showed
signs of illness or suffering. All animal studies were performed according to
the Animals Scientiﬁc Procedures Act 1986 (ASPA), as recently revised to
transpose European Directive 2010/63/EU on the protection of animals
used for scientiﬁc purposes. Mouse cohort numbers were estimated to
detect (Po0.05) a difference in survival of 2 months or greater with a
power of 0.8, assuming a standard deviation of 2.2 months (http://www.
biomath.info/power/ttest.htm).
Competitive hematopoietic progenitor transplantation
C57BL/6 mice (n= 4 per group) were irradiated with a lethal dose of 2 × 500
rad. They were then injected into the tail vein with a combination of
250 000 lineage negative bone marrow cells (lin−) from C57BL/6.SJL
(Sf3b1+/+, CD45.1) mice and 250 000 lin− cells from Sf3b1K700E/+ (CD45.2)
mice plus 250 000 whole bone marrow (BM) rescue cells from C57BL/6/6.
SJL (CD45.1/CD45.2) mice. Control animals were injected with 1 × 106
whole BM cells from C57BL/6/6.SJL (CD45.1/CD45.2). Blood counts and
FACS analysis were performed after 1, 2 and 4 months. Samples were
stained with CD45.1-APC (Becton Dickinson, Oxford, UK) and CD45.2-FITC
(Becton Dickinson) antibodies run on Becton Dickinson LSFR Fortessa and
analyzed with Flowjo 7.6.5 (FlowJo, LLC, San Diego, CA, USA).
Immunophenotyping
For mouse phenotyping peripheral blood and bone marrow from femurs
were collected from animals of different genotypes and processed as
previously described.16 For ﬂow analysis, samples were stained with
Gr1-PE (Miltenyi Biotec, Woking, UK), CD11b (Mac1)-FITC (Becton
Dickinson), CD71-PE (Becton Dickinson), Ter119-Fitc (Becton Dickinson).
For analysis of progenitor populations BM cells were lysed with Red Blood
Cell buffer (NH4, Cl) and then enriched with the EasySep Hematopoietic
Progenitor Cell Isolation Kit (StemCell Technologies, Cambridge, UK)
followed by staining with following antibodies Sca1-PB, c-KIT-Acy7,
CD34-FITC, Flk2-PeCy5, Cd16/32-PE, CD150-PeCy7, CD48-APC.
RNA isolation and analysis
Whole BM cells were harvested from femurs of Sf3b1+/+ and Sf3b1K700E/+
animals. lin− cells were isolated with MACS separation system (Miltenyi
Biotec) following standard protocol. RNA from whole BM was isolated
using an RNA isolation Kit (Qiagen, Manchester, UK) and RNA from lin− cells
with PicoPure RNA Isolation System (Thermo Fisher, Hempstead, UK).
Sequencing was performed on the Hiseq2000 V4 sequencing platform
(llumina, San Diego, CA, USA). Sequence data have been deposited in
ArrayExpress with the accession number E-ERAD-379. All RNA-seq data
were analyzed as described previously.13 RNA-seq datasets have been
deposited at the NCBI GEO and are available under accession number GEO:
GSE72790. STAR alignment software was used to align raw sequence
fragments to the hg19 human reference genome.17 Junction percent
spliced-in (PSI) was calculated for any two or more splice junctions that
share a junction boundary and have alternative end points by dividing the
raw count of each junction species by the total sum of junction counts that
also share that boundary. Intron retention was factored into PSI
calculations by counting reads that aligned completely to exon–intron
boundaries, deﬁned as 6 basepair (bp) windows, 3 bp in the exon and 3 bp
in the intron. We used a moderated t-test from the stastical package
limma18 to determine the signiﬁcance of PSI measurements. We used the
Gencode v19 transcriptome annotation to evaluate whether junction
boundaries were equivalent to known exon boundaries (that is, junction
novelty). Gene counts were obtained using the Sailﬁsh package,19 and
differential gene expression calculated using edgeR.20 All P-values were
corrected using the Benjamini–Hochberg procedure and q-values o0.05
were considered signiﬁcant.
Nested PCR for lariat sequencing
Gene-speciﬁc reverse transcription of the endogenous lariat region was
done using Superscript IV (Invitrogen) and primer C (Supplementary Table 2).
The resulting cDNA was used for nested PCR reactions using Platinum Taq
DNA polymerase (Invitrogen) and two sets of primers, outer primers
(C and D) followed by inner primers (A and B) (Supplementary File 3). The
PCR product from the second reaction was run on 2.0% agarose gel and
gel-extracted for Sanger sequencing. The sequencing data were analyzed
using Mutation Surveyor software.
Statistical analyses
Blood counts and cellular compartment sizes were compared using
unpaired t-test. Mouse survival was compared using the Kaplan Meier
estimator. Adenine counts near canonical vs aberrant splice junctions and
expression levels of transcripts that were NMD-predicted vs non-NMD
predicted were compared using the Kruskal H test (Figure 3). Comparison
of RNA-seq transcript levels was performed using edgeR20 (Figure 4).
Impaired splicing in Sf3b1K700E knock-in mice
A Mupo et al
721
Leukemia (2017) 720 – 727
RESULTS
Conditional Sf3b1ﬂox-K700E/+ mice were generated by targeted
modiﬁcation of the Sf3b1 locus in JM8 mouse embryonic stem
cells (ESCs)14,21 (Figure 1a and Supplementary Figures 1 and 2). To
ensure that normal mRNA splicing was retained, the targeted
allele was designed to express normal SF3B1 protein via a part-
codon optimized Sf3b1 exon 12-25 cDNA (Figure 1a and
Supplementary Figure 3). After germline transmission, a down-
stream neomycin cassette was removed in vivo through mating
with Rosa26-FLPe mice,22 to generate the conditional
Sf3b1ﬂox− K700E allele (Supplementary Figure 3). The Sf3b1K700E
mutant allele could then be expressed after Cre-loxP recombina-
tion (Figure 1a and Supplementary Figure 4).
To activate Sf3b1K700E in hematopoietic stem cells, we crossed
Sf3b1ﬂox-K700E/+ and Mx1-Cre23 mice, treated 20 double transgenic
and 20 control (wild type and Sf3b1ﬂox-K700E/+; Mx1-Cre-, henceforth
referred as WT) 4- to 6-week-old mice with polyinosinic-
polycytidylic acid (pIpC) and monitored the animals longitudinally.
Monthly blood counts from mutant mice (henceforth referred to
as Sf3b1K700E/+) showed a progressive normocytic anemia com-
pared to wild type, but no signiﬁcant differences in white blood
cell (WBC) or platelet (PLT) counts (Figure 1b). Cytological
examination of the bone marrow of Sf3b1K700E/+ mice showed
no signiﬁcant dysplasia and no ring sideroblasts (Figure 1c). Bone
marrow (BM) histology did not reveal any signiﬁcant morpholo-
gical differences between WT and Sf3b1K700E/+ mice, but did show
a moderate overall increase in iron deposits in the latter
(Figure 1d). At a median follow-up of 83 weeks, mutant animals
did not show altered survival or increased signs of illness when
compared to WT controls (Supplementary Figure 5a).
To investigate the consequences of Sf3b1K700E expression on
hematopoiesis in greater detail, we analyzed equal numbers of WT
and mutant bone marrow cells harvested 4 weeks after pIpC
injection by ﬂow cytometry. We found that Sf3b1K700E/+ mice
showed a signiﬁcant decrease in the number of phenotypically
deﬁned hematopoietic stem cells (HSCs), but no change in the size
of the LMPP, GMP, CMP and MEP progenitor compartments
compared to WT littermates (Figure 2a). By contrast, Sf3b1K700E/+
6 9 11 12 17 19 22
221917121196
c/o ex12-25
15
*
6 9 11 12 17 19 2215
*
Sf3b1+
(wild type)
Sf3b1flox-K700E
(pre-Cre)
Sf3b1K700E
(post-Cre)
Sf3b1 alleles
WT K700E/+
WT K700E/+
WT K700E/+
WT K700E/+
Time after pIpC injection(months)
PL
T
(x
10
6 /m
l
W
B
C
(x
10
6 /m
l
M
C
V
(fl
)
H
b
(g
/d
l)
x50
x50
x80
x20
Sf3b1K700E/+
Figure 1. Sf3b1K700E/+ mice develop progressive normocytic anemia without ring sideroblasts. (a) Sf3b1 alleles in study mice. The conditional
(pre-Cre) allele contains a ﬂoxed splice trap cassette inserted within intron 11 of the gene. This begins with a splice acceptor site (SA) splicing
in-frame into exons 12–25 of a partially codon-optimized (c/o) Sf3b1 cDNA and ending with a polyadenylation signal (pA). This allele therefore
expresses a chimeric mRNA, which is translated into the wild-type (WT) SF3B1 protein. Downstream of this, the endogenous exon 15 (red) was
mutagenized to encode the K700E mutation. After Cre-mediated excision of the trap cassette, the recombined allele (post-Cre) expresses
Sf3b1-K700E. (b) Serial blood counts highlight a progressive normocytic anemia in Sf3b1K700E/+ compared to age-matched WT mice. Platelet
(PLT) and leukocyte counts (WBC) were not different between mutant and WT mice. (c) Examination of Sf3b1K700E/+ bone marrow cytospins
showed no signiﬁcant evidence of dysplasia (upper panel) and Perl staining demonstrated macrophage iron (arrows), but no ring
sideroblasts (lower panel). (d) In keeping with the cytological ﬁndings, histological examination did not show signiﬁcant dysplasia (upper
panel), although Perl staining did reveal increased iron deposits in mutant bone marrow macrophages (lower panel). Hb, hemoglobin
concentration; MCV, mean corpuscular volume.
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animals showed a small but signiﬁcant increase in the number of
Gr1+/Mac1+ double-positive bone marrow cells (Supplementary
Figure 5b), and in the erythroid compartment there were no
differences in the frequency of Ter119+/CD71+ early erythroid
cells, but a relative decrease of the more mature Ter119+/CD71low/
FSClow population24 (Figure 2b), indicative of impaired terminal
erythroid differentiation similar to that observed in human MDS.25
Next, as SF3B1-K700E behaves like an initiating mutation in
MDS7 and can also drive clonal hematopoiesis in elderly
individuals,8 we wanted to investigate if it confers a ﬁtness
advantage to murine HSCs. To test this, we performed competitive
transplantation assays in lethally irradiated syngeneic (C57BL/6)
recipient mice. These experiments were performed in both young
(2 months) and old (12 months) animals to investigate the
possibility that age-related changes in recipient mice may
inﬂuence the repopulating ﬁtness of Sf3b1K700E/+ mutant stem
cells.26 Experimental mice were transplanted with an equal
number (2.5 × 105) of bone marrow lineage negative (lin− )
progenitor cells from WT (CD45.1) and Sf3b1K700E/+ (CD45.2) mice,
as well as 2.5 × 105 whole bone marrow (rescue) cells from
Sf3b1+/+ (CD45.1/CD45.2) animals. The control group was
transplanted with rescue cells from whole bone marrow
(CD45.1/CD45.2 = 1 × 106). We found that although Sf3b1K700E/+
cells did show good engraftment at 1 month post transplantation,
they displayed a signiﬁcant decline in their white blood cell
progeny after 4 months compared to WT cells. This was true for
both young and old recipients (Figure 2c). Similar results were
obtained using a different Sf3b1K700E/+ donor mouse.
Since SF3B1 mutations affect pre-mRNA splicing and conse-
quently gene expression,13 we performed mRNA sequencing from
whole bone marrow (BM) and lin− progenitors of Sf3b1K700E/+ and
WT animals. Firstly, we observed that in Sf3b1K700E/+ mice
transcript levels of the mutant (K700E) and wild-type Sf3b1
mRNAs were very similar (Supplementary Table 3), conﬁrming that
expression from the targeted allele was not altered by genetic
modiﬁcation of the locus. We next sought to identify aberrant
splicing events associated with Sf3b1-K700E using splice site
analysis of RNAseq data from Sf3b1K700E/+ and WT BM cells as we
described before13 (also see Materials and Methods). Compared to
WT we identiﬁed 719 aberrant events in lin− and 293 in whole BM
cells from Sf3b1K700E/+ mice. The dominant type of aberrant
splicing event was increased usage of cryptic 3′ splice sites (3′ ss)
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Figure 2. Effects of mutant Sf3b1K700E/+ on hemopoietic stem and progenitor cells. (a) Flow cytometric analysis of bone marrow cells from
Sf3b1K700E/+ mice showed a signiﬁcant decrease of phenotypically deﬁned HSCs compared to WT animals, but no differences in LMPP, GMP,
CMP or MEP progenitor numbers (n = 4). (b) Early erythroid cells (Ter119+/CD71+) were unchanged in number, but there was a reduction in
mature Ter119low/CD71+ erythoid cells in Sf3b1K700E/+ animals. (c) Competitive transplantation of bone marrow lin− cells from WT (CD45.1) and
Sf3b1K700E/+ (CD45.2) into young (2 months) or old (1 year) syngeneic (C57BL/6) recipients (n= 4 per group). Results shows that, after good
initial engraftment (1 month), Sf3b1K700E/+ (CD45.2) progenitor cells were steadily outcompeted by co-transplanted WT (CD45.1) cells. Bars in
(a, b) and datapoints in (c) show mean± standard error of the mean.
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(Figure 3a), the majority of which were novel, that is, not reported
in current transcriptome annotations. Aberrant splice sites were
located within a narrow window of 15–24 nucleotides (nt)
upstream from the canonical 3′ ss (Figure 3b) and associated
with sequence features, including a shorter polypyrimidine tract
and an enrichment of adenines at positions -8 to -18 upstream of
the cryptic 3′ ss (Figures 3c and d), as described for human cancers
with SF3B1 mutations.13 Since SF3B1 is known to play a major role
in U2 snRNP recruitment to the splicing branchpoint (BP), we
performed lariat sequencing to identify BPs in aberrantly spliced
mouse mRNAs. One example we identiﬁed was the UgdhmRNA, for
which the BP was located 16 nt upstream of the aberrant AG splice
acceptor site that notably was not conserved in the human genome
(Figure 3e). The Get4 gene showed similar features (Supplementary
Figure 6). These observations demonstrate that, as shown recently
for human cancers,11 there is a distinct usage of cryptic BPs in cells
expressing mutant SF3B1 in our mouse model.
Reconstruction of annotated transcripts that used aberrant 3′
splice sites in the lin− RNAseq dataset revealed that approximately
42% of affected genes gain a premature termination codon in all
isoforms, which is predicted to result in mRNA degradation through
the nonsense-mediated decay (NMD) pathway. Genes for which
NMD was predicted (n = 190) showed signiﬁcantly lower mRNA
expression levels than those for which NMD was not predicted
(n = 225) (P = 3.92 × 10−13, Kruskal H test, Figure 3f). Further-
more, looking at the transcriptome as a whole, we found that most
(408 of 511) differentially expressed genes in lin− cells were
downregulated (discussed below). These ﬁndings demonstrate that
Sf3b1-K700E is associated with abnormal splicing in hematopoietic
stem/progenitor cells, primarily through the use of aberrant 3′-ss
that are thought to result in NMD, and this is associated with
signiﬁcant downregulation of a large number of mRNAs.
Unbiased gene set enrichment analysis (GSEA) of the genes
differentially expressed in Sf3b1K700E/+ revealed an enrichment of
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Figure 3. Aberrant 3′ splicing is the dominant abnormality associated with Sf3b1-K700E in bone marrow cells. (a) Types and relative
frequencies of aberrant splicing events in Sf3b1K700E/+ vs WT BM and lin− cells. Most are alternative 3′ splicing events, of which many are
shared between BM and lin− cells (Venn diagram). (b) Distribution of distances of aberrant 3′ss (AG) from the downstream canonical 3′ss in
Sf3b1K700E/+ BM and lin− RNA. This distance is signiﬁcantly shorter than that of known cryptic ss annotated in Ensembl (all mouse junctions for
the ﬁrst AAG, TAG or CAG within 100 nt upstream from the canonical 3' splice site are considered). (c) Motif frequency plots for Sf3b1K700E/+ BM
and lin− samples contrasting aberrant and canonical 3′ ss sequences, showing an enrichment of adenines in the former. (d) Signiﬁcant
enrichment in adenines in positions -8 to -18 upstream of aberrant 3′ ss (AG) compared to the canonical junctions from Sf3b1K700E/+ BM and
lin− cells. (e) Lariat sequencing of the aberrant splice site of the Ugdh gene in Sf3b1K700E/+ mice, highlighting the location of the aberrant
branch point (upper panel; the top trace is the raw data from Sanger sequencing and bottom is deconvoluted data from Mutation Surveyor).
The gene is not misspliced at this locus in human SF3B1-mutant cancers as it does not retain the AG dinucleotide required for aberrant
splicing (lower panel). (f) Association between aberrant splicing and gene expression. Transcripts that are NMD-predicted are signiﬁcantly
downregulated compared to transcripts that are non-NMD predicted (p = 3.92 × 10− 13, Kruskal H test).
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genes involved in RNA processing, splicing and transcription.
Interestingly, similar enrichment was observed in human MDS11
(Supplementary Figure 7).
Broad transcriptomic changes were observed in human cancers
with SF3B1 mutations including MDS,11,27 and we recently
described the aberrant splicing patterns in such cancers.13 Here
we perform a similar analysis on RNAseq data from Sf3b1K700E/+
mice and report that for aberrant 3′ splice sites with upstream
cryptic AGs, splicing abnormalities are strikingly similar to those
seen in human cancer samples, including the aberrant splice site
consensus sequence (Figure 4a) and distance of aberrant 3′ splice
sites from the canonical ones (Figure 4b). However, despite these
striking similarities, there was minimal overlap between aberrantly
spliced genes in mouse vs human cells. In fact, comparing the two
datasets we found that only ~ 5% (17/360) of the aberrantly
spliced genes in mouse Sf3b1K700E/+ lin− cells were also aberrantly
spliced in human samples (Figure 4c). To look at this more closely,
we compared the nucleotide sequences at the location of the
aberrant 3′ splice sites identiﬁed in human SF3B1-mutant
cancers,11,13 including MDS, and those identiﬁed in our
Sf3b1K700E/+ mouse BM and lin− cells with the equivalent positions
in the genome of the other species, examining the conservation of
the invariant AG dinucleotides at the splice sites and that of the
upstream 35nt. We ﬁrst examined genes thought to have a role in
the formation of ring sideroblasts in human SF3B1-mutant MDS,
namely TMEM14C25 and ABCB7,28,29 for which aberrant 3′ splicing
was observed in humans, but not in Sf3b1K700E/+ mice. The human
TMEM14C aberrant splice site AG was not conserved in mice, while
for ABCB7, although the AG dinucleotide was conserved, it was
located 2 nt upstream and was preceded by a poorly conserved
sequence that deviated signiﬁcantly from the aberrant splicing
consensus (Figure 4d). We then looked at the 360 canonical
junctions with aberrant upstream 3′ splice sites in Sf3b1K700E/+ lin−
cells and found that 268 were conserved in the human genome.
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Figure 4. Mouse and human SF3B1-K700E share aberrant splicing properties, but affect different mRNA transcripts. (a) Comparison of
consensus sequences upstream of aberrant and canonical 3′ ss shows a striking preservation of these motifs between mouse Sf3b1K700E/+ lin−
cells and several human SF3B1-mutant cancers. (b) Distribution of distances of aberrant 3′ss (AG) from the downstream canonical AG is also
strikingly similar between mouse Sf3b1K700E/+ lin− cells and human cancer samples. (c) By contrast, a comparison of genes found to be
aberrantly spliced in human vs mouse samples shows minimal overlap. (d) Poor sequence preservation in the mouse of the aberrant splice
sites affecting human genes TMEM14C and ABCB7 that are thought to trigger the formation of ring sideroblasts in MDS. (e) Volcano plots
comparing mRNA expression between Sf3b1K700E/+ vs Sf3b1+/+ BM and lin− cells. The mRNA expression of genes Slc25a37, Tmem14c, Alas2 and
Abcb7, thought to be involved in the formation of ring sideroblasts, is not signiﬁcantly altered by the K700E mutation in mice. The number of
aberrant events used to generate images in a and b is indicated in b (brackets). BRCA, breast cancer; CLL, chronic lymphocytic leukemia; MDS,
myelodysplastic syndromes; SKCM, skin cutaneous melanoma.
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Of the 268 human junctions only 125 contained both a potential
cryptic AG in the range preferred by SF3B1/Sf3b1 mutants
(-5 to -20nt) and a potential branchpoint adenosine at -8 to -18
from the cryptic AG, indicating that less than 35% of mouse
junctions with aberrant 3′ splice sites had the hypothetical
capacity for aberrant splicing in human cells. Of these 125
potential aberrant junctions, only 53 (14.7% of total) were found to
be spliced in any human MDS sample, indicating that the limited
conservation between mouse and human intronic sequences is
responsible for the differences in misspliced mRNAs in the two
species. We also noted that both Tmem14c and Abcb7 as well as
the Alas2 (heme biosynthesis) and Slc25a37 (mitochondrial iron
importer) genes that are downregulated in human SF3B1-mutant
MDS11 did not display altered expression in Sf3b1K700E/+ lin− or
whole BM cells (Figure 4e).
DISCUSSION
In order to understand the molecular and phenotypic conse-
quences of SF3B1 mutations on hematopoiesis and their role in
the pathogenesis of clonal blood disorders, we generated a knock-
in conditional mouse model of SF3B1-K700E, the most common
mutation in human MDS. Our conditional allele preserved wild-
type Sf3b1 expression, thus avoiding any confounding effects of
reduced Sf3b1 levels on hematopoiesis11,30 or other develop-
mental effects. Conditional activation by Mx1-Cre of the Sf3b1-
K700E mutation in Sf3b1ﬂox− K700E/+ mice then enabled direct
comparison to wild-type (WT) isogenic hematopoietic progenitors
at the molecular and phenotypic level. At the molecular level, we
report that the splicing defect seen in Sf3b1K700E/+ hematopoietic
progenitors closely mimicked that described in human MDS, in
sharing a strikingly similar splice-site consensus sequence and
distance from the aberrant splice site AG. Furthermore, as was
recently described for human cancer samples,31,32 we show that
aberrant BP recognition is central to the disrupted function of
mutant SF3B1 in our mice. However, despite the closely similar
properties of human and mouse SF3B1 mutants, we found that
misspliced transcripts differed signiﬁcantly between mouse and
human as a result of the relatively poor interspecies conservation
of intronic sequences able to function as aberrant splice sites.
Interestingly, a recent study describing a murine model of U2AF1-
S34F, another MDS-associated splicing gene mutation associated
with aberrant 3′ splice acceptor site recognition, also showed
limited mouse–human overlap of mispliced transcripts.33 The
mouse–human overlap appeared greater for a mouse model of
SRSF2 mutations (SRSF2-P95H), another commonly mutated gene
in human MDS, possibly because the splicing aberration involves
alternative exonic sequences, which are more likely than intronic
ones to be conserved.34
With regard to erythropoiesis, Sf3b1K700E/+ mice showed
impaired terminal erythroid differentiation, associated with
progressive normocytic anemia without ring sideroblasts. In
human SF3B1-mutant MDS, ring sideroblasts are thought to arise
as a result of aberrant splicing of key genes involved in
heme biosynthesis, such as ABCB7, TMEM14C, ALAS2 and
SLC25A37.11,25,30,35 In keeping with the mouse–human differences
in target transcripts, we did not ﬁnd the splicing or expression
levels of any of these genes to be noticeably disrupted by Sf3b1-
K700E, and, consistent with this, did not identify ring sideroblasts
in the bone marrow of mutant mice. Of note, ring sideroblasts
were not observed in single-gene knock-out mice for either
Alas236 or Abcb7,37 suggesting that sideroblast formation may
require simultaneous reduction in the levels of multiple proteins
involved in both heme biosynthesis (ALAS2, TMEM14C) and
mitochondrial iron transport (ABCB7 and SLC25A37), and may
therefore be difﬁcult to replicate in single-gene targeting models.
In this light, the development of anemia in Sf3b1K700E/+ mice may
be at least in part due to globally disrupted splicing rather than
effects on particular genes. Aberrant splicing leads to the
introduction of premature termination codons, which can in turn
lead to the generation of truncated proteins with potential toxic
effects on cells, leading in this instance to anemia and impaired
iron utilization manifested as excess hemosiderin deposition in the
bone marrow of Sf3b1K700E/+ mice. An alternative or additional
explanation may reside in the fact that both mouse and human
cells displayed aberrant expression of genes involved in splicing
and RNA processing itself (Supplementary Figure 7), which may be
a response to, rather than a result of, globally disrupted splicing. In
fact there is evidence that when their intracellular concentrations
become too high, some splicing factors regulate their own
expression by targeting their mRNAs for NMD.38
Beyond erythropoiesis, Sf3b1K700E/+ mice had reduced numbers
of HSCs and displayed a myeloid cell bias. Furthermore,
investigation of the self-renewal potential of Sf3b1K700E/+ HSCs as
determined by their repopulating ability in competitive transplan-
tation assays into either young or old recipient mice revealed a
ﬁtness disadvantage of mutant over wild-type HSCs. This contrasts
with observations that mutant SF3B1 can drive clonal hematopoi-
esis and can even be the sole identiﬁable driver mutation in
human MDS.7,9 However, observations that SF3B1 mutations
appear to selectively impart a clonal advantage on HSCs of
elderly, but not young, individuals suggest that the phenomenon
is context dependent even in humans.26 Furthermore, a lack of
clonal HSC advantage was a feature of other mouse models of
MDS-associated mutations, including ASXL1,39 U2AF133 and
SRSF2,34 all of which can also drive clonal hematopoiesis in
humans,40,41 proposing that factors other than somatic mutations
may be operative in the development of MDS.26
The fact that disruption of a process as central to cellular
function as RNA splicing can have detrimental effects on cells is
unsurprising and further augments the conundrum of how
particular spliceosome gene mutations can instead impart a
survival/ﬁtness beneﬁt upon human HSCs, albeit in a context-
dependent manner.8,26 This remains the least-well-understood
feature of spliceosome gene mutations, and our data propose that
the different phenotypic effects of spliceosome gene mutations in
MDS (e.g. anemia, ring sideroblasts, clonal expansion) may have
distinct molecular causes. Future studies aimed at deciphering the
mechanisms underlying these phenotypes should exploit both
the similarities and the differences in the transcriptional
consequences of these mutations between mice and humans, as
a means of identifying their respective etiologies.
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